NCT07504783Completed
A Study to Evaluate the Real-world Experience and Satisfaction Associated With Ofatumumab
A Study Investigating Drivers of Physician and Patient Satisfaction Towards Treatment
Source: ClinicalTrials.gov · Last updated 15 Jun 2026
Brief summary (registry, in English)
The aim of this study was to assess physician and patient satisfaction with ofatumumab using data collected from physicians and their multiple sclerosis (MS) patients in real-world clinical practice across the United Kingdom (UK), France, Germany, Italy, Spain, China, Japan, and Brazil.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 261 (actual)
- First submitted
- 26 Mar 2026
- Start date
- 22 Jan 2026
- Primary completion date
- 30 Apr 2026
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Multiple sclerosis
- NCT number
- NCT07504783
What you commit to
- Study type: Observational
- Participants enrolled: 261
- From 22 Jan 2026 to the primary completion date, 30 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Criteria the registry did not label
- Physician inclusion criteria:
- Physicians must be actively involved in the treatment/management of patients with MS
- Consult with a minimum of 16 MS patients (\>5 in Japan and China, \>10 in Brazil) per month
- Patient inclusion criteria:
- Patients for whom physicians complete a Physician Completed Patient Record Form (PRF), and therefore are included in the pool of data for analysis, are based on the following criteria:
- Patients who had a physician-made diagnosis of MS before or at the time of data collection
- Patients must not currently be involved in a clinical trial
- Patients ≥18 years old
- For patients included in the ofatumumab sample, they must have been receiving ofatumumab for \>12 months at the time of data collection
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Novartis Coordinator of this site? Confirm its status | Basel | Switzerland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.